| 129.46 0.18 (0.14%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 151.43 | 1-year : | 176.87 |
| Resists | First : | 129.64 | Second : | 151.43 |
| Pivot price | 128.8  |
|||
| Supports | First : | 128.54 |
Second : | 127.85 |
| MAs | MA(5) : | 129.38 |
MA(20) : | 128.66 |
| MA(100) : | 103.69 |
MA(250) : | 98.78 |
|
| MACD | MACD : | 2.6 |
Signal : | 3.4 |
| %K %D | K(14,3) : | 84.2 |
D(3) : | 85 |
| RSI | RSI(14): 76.6 | |||
| 52-week | High : | 129.64 | Low : | 73.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BPMC ] has closed below upper band by 19.3%. Bollinger Bands are 86.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 129.62 - 130.25 | 130.25 - 130.87 |
| Low: | 127.56 - 128.37 | 128.37 - 129.17 |
| Close: | 127.97 - 129.25 | 129.25 - 130.5 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Mon, 15 Sep 2025
Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction - Business Wire
Fri, 18 Jul 2025
Sanofi completes $9.1 billion acquisition of Blueprint Medicines, Nasdaq delisting follows - Investing.com
Thu, 17 Jul 2025
Press Release: Sanofi completes acquisition of Blueprint Medicines - Yahoo Finance
Thu, 10 Jul 2025
Blueprint Medicines stock hits all-time high at 129.49 USD - Investing.com
Mon, 02 Jun 2025
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover - Investopedia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 109.1 (%) |
| Shares Short | 3,130 (K) |
| Shares Short P.Month | 5,670 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.3 |
| Profit Margin | -27.8 % |
| Operating Margin | -27.5 % |
| Return on Assets (ttm) | -9.8 % |
| Return on Equity (ttm) | -47.8 % |
| Qtrly Rev. Growth | 55.5 % |
| Gross Profit (p.s.) | 8.39 |
| Sales Per Share | 8.7 |
| EBITDA (p.s.) | -2.46 |
| Qtrly Earnings Growth | -99.5 % |
| Operating Cash Flow | -146 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -51.58 |
| PEG Ratio | 0 |
| Price to Book value | 24.42 |
| Price to Sales | 14.87 |
| Price to Cash Flow | -57.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|